Chronic Plaque Psoriasis - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 100 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chronic Plaque Psoriasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2014', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Plaque Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Plaque Psoriasis - Overview 9
Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis 10
Chronic Plaque Psoriasis - Therapeutics under Development by Companies 11
Chronic Plaque Psoriasis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Chronic Plaque Psoriasis - Products under Development by Companies 15
Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
AbGenomics International, Inc. 17
Actelion Ltd 18
Almirall, S.A. 19
ApoPharma Inc. 20
Biotest AG 21
Boehringer Ingelheim GmbH 22
Can-Fite BioPharma Ltd. 23
Eli Lilly and Company 24
Mitsubishi Tanabe Pharma Corporation 25
Novartis AG 26
OPKO Health, Inc. 27
Pfizer Inc. 28
Sandoz Inc. 29
Sun Pharmaceutical Industries Inc. 30
Takeda Pharmaceutical Company Limited 31
XenoPort, Inc. 32
Chronic Plaque Psoriasis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
AbGn-168H - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
adalimumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
adalimumab biosimilar - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
baricitinib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BI-655066 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CF-101 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CJM-112 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
etanercept biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
etanercept biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ixekizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LAS-41008 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
lunacalcipol - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MT-1303 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
namilumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
orilotimod - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PF-06263276 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ponesimod - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
tildrakizumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
tregalizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
XP-23829 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Chronic Plaque Psoriasis - Recent Pipeline Updates 70
Chronic Plaque Psoriasis - Dormant Projects 92
Chronic Plaque Psoriasis - Discontinued Products 93
Chronic Plaque Psoriasis - Product Development Milestones 94
Featured News & Press Releases 94
Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 94
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 94
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 96
Nov 08, 2010: Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in RA 97
Jan 20, 2010: Fully Human Monoclonal Anti-TNF-alpha Antibody Humira Receives Approval as Japan's First Biological Agent for Psoriasis 97
Dec 20, 2007: Humira got approved in the European Union used for the treatment of moderate-to-severe Plaque Psoriasis. 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Tables
Number of Products under Development for Chronic Plaque Psoriasis, H2 2014 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Chronic Plaque Psoriasis - Pipeline by AbbVie Inc., H2 2014 16
Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H2 2014 17
Chronic Plaque Psoriasis - Pipeline by Actelion Ltd, H2 2014 18
Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H2 2014 19
Chronic Plaque Psoriasis - Pipeline by ApoPharma Inc., H2 2014 20
Chronic Plaque Psoriasis - Pipeline by Biotest AG, H2 2014 21
Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 22
Chronic Plaque Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 23
Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H2 2014 24
Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 25
Chronic Plaque Psoriasis - Pipeline by Novartis AG, H2 2014 26
Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H2 2014 27
Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H2 2014 28
Chronic Plaque Psoriasis - Pipeline by Sandoz Inc., H2 2014 29
Chronic Plaque Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H2 2014 30
Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 31
Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 41
Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 70
Chronic Plaque Psoriasis - Dormant Projects, H2 2014 92
Chronic Plaque Psoriasis - Discontinued Products, H2 2014 93